Skip to main content
. 2022 Sep 7;10(9):2216. doi: 10.3390/biomedicines10092216

Figure 2.

Figure 2

Antitumor effect of ErbB2CAR in an ovarian mouse model. Mice were intraperitoneally engrafted with 2 × 106 luciferase-expressing NAR tumor cells (NARLUC). After 20 days, the mice were treated with ErbB2CAR (2.5 × 106 IP or 10 × 106 IP or 10 × 106 IV), with non-infected T cells (UNT), or left untreated (Control). (A) Tumor burden assessment of NARLUC in treated mice as imaged by IVIS at the indicated days. The arrowhead indicates CART injection at day 20. (B) Summary of averaged radians (p/s/cm2/sr) of three in vivo experiments. Each group includes 10–18 mice ± SEM. Data were analyzed by 2-way ANOVA test of ErbB2CAR (2.5 × 106 IP or 10 × 106 IP) versus UNT * p < 0.01, and 10 × 106 IP versus 10 × 106 IV * p < 0.05 ErbB2CAR 10 × 106 IV versus UNT. (C) Kaplan–Meier survival curves of mice in different treatment groups. Each group included 10–18 mice ± SEM. * p < 0.0001 ErbB2CAR 10 × 106 IP versus 10 × 106 IV and ErbB2CAR 10 × 106 IP versus UNT. * p < 0.05 ErbB2CAR 10 × 106 IP versus UNT. ErbB2CAR 10 × 106 IV versus UNT was not significant. (D) The mice were euthanized 45 days post-NAR-LUC injection. Cells from ovaries were isolated, stained with anti-human ErbB2-APC, and analyzed by flow cytometry. Each group includes an average of 5–11 mice ± SEM. Data were analyzed by 1-way ANOVA test * p < 0.05.